Welcome to our dedicated page for Vaccinex news (Ticker: VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.
Vaccinex, Inc. reports developments as a clinical-stage biotechnology company focused on investigational antibody therapies for neurodegenerative disease and cancer. Its lead program, pepinemab, is an anti-SEMA4D antibody being developed for Alzheimer’s disease and other neurological indications, with additional clinical work in cancer, including head and neck cancer and melanoma immunotherapy settings.
Company news commonly covers pepinemab clinical data presentations, financial results, development financing, and corporate updates tied to listing status and OTC quotation. Vaccinex also reports activity involving its ActivMAb® platform, which uses viral display of complex antigens to support antibody discovery collaborations and project agreements.
Vaccinex (OTCMKTS: VCNX) reported it released its 2025 annual financial results for the year ended December 31, 2025 and posted the financial statements on its website on April 29, 2026. The company is a clinical-stage developer of investigational antibody therapies for Alzheimer’s, Huntington’s, and cancer.
Vaccinex (NASDAQ:VCNX) announced a $60 million revenue‑sharing financing with Pepinemab Development Venture LP to fund an enlarged Phase 2b trial of pepinemab for Alzheimer’s disease on Dec 23, 2025. The deal gives PDV 50% of future economic proceeds from neurological pepinemab licenses and 25% for other indications. Company cites prior SIGNAL‑AD Phase 1/2a and HD Phase 2 data showing tolerability, biomarker effects, reduced Ast10 astrocyte representation, and signals of slowed cognitive decline; results were reported at CTAD on Dec 3, 2025.
Vaccinex (NASDAQ: VCNX) announced new clinical data demonstrating pepinemab's mechanism in enhancing immunotherapy effectiveness, to be presented at the 2025 AACR Annual Meeting in Chicago on April 29, 2025.
The data reveals that pepinemab, a Semaphorin 4D blocking immunotherapy, induces mature lymphoid structures (TLS) that correlate with durable clinical benefits in both metastatic melanoma and head and neck cancer patients. By blocking SEMA4D inhibitory signals to Dendritic Cells, pepinemab enables coordinated immune cell interactions within TLS, amplifying mature T cell responses.
Key findings show pepinemab's ability to transform immunologically 'cold' tumors into 'hot' immune centers in HPV-negative and PD-L1-low head and neck cancer. In melanoma patients, neoadjuvant treatment with pepinemab enhanced TLS maturity and correlated with longer recurrence-free survival when combined with immune checkpoint inhibitors.
Vaccinex (VCNX) has announced its decision to voluntarily delist its common stock from the Nasdaq Stock Market. This follows a suspension of trading since December 18, 2024, and a notice dated December 16, 2024, from the Nasdaq Hearings Panel determining to delist the company's securities.
The biotechnology company plans to file a Form 25 with the SEC around March 17, 2025, to formally remove its listing. Despite the delisting, Vaccinex intends to continue developing its lead product, pepinemab, targeting Alzheimer's disease and cancer treatments through partnerships, grants, and alternative financing methods.
Vaccinex (VCNX) received a delisting notification from Nasdaq on December 16, 2024, due to failure to maintain the required minimum of $2.5 million in stockholders' equity under Nasdaq Listing Rule 5550(b)(1). Trading of VCNX common stock will be suspended on Nasdaq effective December 18, 2024. Following the suspension, the company's shares are expected to be quoted on the OTC Markets Group under the same symbol 'VCNX'.
Vaccinex (VCNX) reported Q3 2024 financial results and provided updates on its Alzheimer's disease program. The company reported final data from its SIGNAL-AD clinical trial, showing that pepinemab treatment slowed cognitive decline in patients with early signs of cognitive deficits. Cash and equivalents were $2.9 million as of September 30, 2024. The company recently completed a private placement raising $2.15 million and received approximately $6.2 million from warrant exercises. Q3 net loss was $5.7 million or $(2.83) per share. The company is currently facing Nasdaq listing compliance issues and has submitted a plan to maintain its listing.
Vaccinex (NASDAQ: VCNX) announced multiple proprietary project agreements with major pharmaceutical companies including Amgen, Merck, Chugai, and others for using its ActivMAb® technology platform. The technology enables expression of complex proteins for antibody discovery, particularly useful for developing immunotherapies. The company will also provide materials to strategic partners like Charles River Labs and OmniAb to support their antibody discovery programs.
Additionally, Vaccinex will present data on successful antibody discovery campaigns at the Society for Immunotherapy of Cancer's 29th Annual Meeting in Houston. The first clinical candidate using this technology (CHS-114) is currently in development by Coherus Biosciences for cancer immunotherapy.
Vaccinex (NASDAQ: VCNX) announced new biomarker data showing that pepinemab enhanced clinical activity of immune checkpoint inhibitors in HPV-negative head and neck cancer (HNSCC). Data from two studies, the Phase 2 KEYNOTE-B84 and a neoadjuvant treatment study, demonstrated that pepinemab combination treatments induced mature lymphoid aggregates correlating with clinical benefit in immunotherapy resistant tumors. The findings will be presented at the Society for Immunotherapy of Cancer's Annual Meeting on November 8th, 2024.
The research suggests pepinemab can overcome limitations of immune checkpoint inhibitors, particularly in patients who typically don't benefit from immune checkpoint monotherapy.
Vaccinex (VCNX) announced new findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease. The study revealed that pepinemab treatment inhibits the expression of plasma GFAP and p-tau 217 biomarkers during Mild Cognitive Impairment (MCI). The treatment showed promising trends in slowing cognitive decline in mild dementia patients with MMSE scores of 22-26. Proteomic analysis of Cerebrospinal Fluid identified several proteins typically increasing during AD progression that were inhibited by pepinemab. Additionally, using a Brain-Chip model, pepinemab demonstrated ability to inhibit or reverse damage caused by toxic alpha synuclein aggregates, suggesting potential applications in other neurodegenerative diseases.